What Melius MicroBiomics does

Melius MicroBiomics is a preclinical-stage biotechnology company developing genetically engineered microbial medicines (GEMM™) for gut inflammation in humans and animals. Founded in 2023 in Vancouver, Canada, as a spin-off of Dr. Deanna Gibson's research lab at UBC Okanagan, the company builds on more than a decade of academic R&D and operates a head office in Vancouver plus an R&D laboratory in Kelowna incubated by Innovate Phytoceuticals. The company's core technology combines two patented genetic platforms — BioPersist™, which equips bacteria with the ttr operon to metabolize inflammation byproducts as an energy source, and BioColonize™, which encodes binding proteins for adherence to intestinal epithelial cells — supplemented by a patent-pending microencapsulation system for targeted gut delivery. The lead product candidate, MMB-003 (EcN::ttr), is an engineered Escherichia coli Nissle 1917 strain that has demonstrated superior preclinical efficacy over 5-ASA, the frontline therapy for inflammatory bowel disease, in rodent and pig colitis models.

The company pursues a multi-segment commercialization strategy covering human therapeutics (ulcerative colitis as the lead indication, with potential expansion into Crohn's disease, metabolic disorders, gut-brain axis indications, and even astronaut gut health), pork industry applications (a feed additive for post-weaning stress in piglets), and companion animal products (cats and dogs). Revenue is not yet generated and pricing is undisclosed, as MMB-003 remains an investigational live biotherapeutic product. The company plans to initiate first-in-human Phase 1a/2a trials in Australia in August 2026 after receiving the OGTR DIR (Dealings Involving Intentional Release) licence (DIR 221) in March 2026. As of the latest reporting, Melius has raised approximately $108 million in total funding, including a $100 million Series A in January 2024, and is preparing for a Nasdaq IPO targeted for 2026. The company's go-to-market combines enterprise regulatory partnerships (UBC licensing, Australian clinical sites), scientific credibility-building through peer-reviewed publications and conferences, and pilot-trial plans for animal health applications.

The customer base is entirely pre-commercial: there are no paying customers today. Intended end-customers span three structurally distinct segments — human IBD patients reached through pharmaceutical licensing or direct commercialization, pork producers reached through feed-additive distribution channels, and companion animal owners reached through veterinary channels. The company is led by CEO Robert Emlyn (biotech entrepreneur, founder of Innovate Phytotechnologies) and scientific founder Dr. Deanna Gibson (UBC professor), with senior leadership including Chief Medical Officer Dr. Emeran Mayer (UCLA), Head of R&D Dr. Kevin Horgan (former Seres Therapeutics, AstraZeneca, Merck), and Co-Founder Celinka Zhou, who is architecting the 2026 Nasdaq IPO roadmap. The team comprises 8+ PhDs across scientific, clinical, regulatory, and commercial functions.

Name

Melius MicroBiomics

Legal name

Melius MicroBiomics Inc.

Website

https://mmblivebio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Melius MicroBiomics is a preclinical-stage Canadian biotech developing genetically engineered microbial medicines (GEMM™) — engineered probiotic strains that thrive in inflamed guts — with a lead candidate (MMB-003) targeting ulcerative colitis, plus animal health applications for pigs and companion animals.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics (Live Biotherapeutic Products)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Non-Human Microbiome Therapeutics (veterinary/animal microbiome interventions) (HLAAAFAL)

Keywords

• Live biotherapeutic products
• Microbiome therapeutics
• Genetically engineered bacteria
• Inflammatory bowel disease
• Animal gut health

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Human Therapeutics (MMB-003): Revenue expected from approval and commercialization of MMB-003 (EcN::ttr) as a prescription live biotherapeutic product for ulcerative colitis and potentially other inflammatory bowel diseases. Currently in clinical trial preparation phase.
2. Animal Health Products: GEMM products for pigs (post-weaning stress) and companion animals (cats & dogs). For pigs, planned as a feed additive to improve feed efficiency and weight gain. Currently planning pilot trials.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Melius MicroBiomics develops genetically engineered microbial medicines (GEMM™) targeting gut inflammation in humans and animals. Its core platforms — BioPersist™ and BioColonize™ — are genetic toolkits licensed from UBC that equip beneficial bacteria to persist in inflamed gut environments and to colonize effectively. The lead human candidate MMB-003 (EcN::ttr) is advancing toward first-in-human clinical trials for ulcerative colitis, with parallel product lines aimed at pig post-weaning stress and companion animal gut health.

Product overview

Melius MicroBiomics is a biotechnology company developing GEMM™ (Genetically Engineered Microbial Medicines), a platform-plus-applications portfolio. The core technology consists of BioPersist™ (persistence platform) and BioColonize™ (colonization platform), enhanced by proprietary microencapsulation for gut delivery. The lead product candidate MMB-003 (EcN::ttr) is being developed for ulcerative colitis in humans, while parallel applications target pig health (post-weaning stress) and companion animals. The company holds patents licensed from UBC for its core genetic platforms.

Differentiator

Problem solved

Functional benefit

Brands

• GEMM™: Genetically Engineered Microbial Medicine - a novel class of therapeutics that harness the natural powers of beneficial bacteria
• BioPersist™
• BioColonize™

Products and services

• MMB-003 (EcN::ttr) Lead product candidate; an engineered Escherichia coli Nissle 1917 strain carrying the ttr operon (BioPersist™ modification) that enables the bacterium to survive and thrive in inflamed intestines. Being developed as a prescription live biotherapeutic product for ulcerative colitis and other IBD indications, with additional potential applications in metabolic disorders and gut-brain axis indications.
• GEMM™ for Pigs Animal-health application of GEMM technology engineered to address post-weaning stress in piglets, designed to reduce post-weaning diarrhea and mortality, improve feed efficiency, and increase average daily weight gain. Planned feed-additive product for commercial pork producers.
• GEMM™ for Companion Animals (Cats & Dogs) Veterinary application of GEMM technology using genetically modified beneficial bacteria tailored for gut health in cats and dogs, leveraging the same BioPersist™ and BioColonize™ platforms used in human therapeutics.

Quantifiable outcome

• No mice developed severe colitis by 16-week mark vs. severe disease in untreated and standard-probiotic groups
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• University of British Columbia (UBC)coreStrategic or Co-development Partner · 21 November 2024UBC finalized a licensing agreement with Melius for Melius' core GEMM™ (Genetically Engineered Microbial Medicine) and related technologies (BioPersist™ & BioColonize™ platforms). Dr. Deanna Gibson's research lab at UBC Okanagan developed the patented technology. UBC is a global leader in scientific innovation, and this partnership advances GEMM platform development toward clinical applications for treating IBD, diabetes, and mood disorders.
• Innovate Phytoceuticals LaboratorycoreStrategic or Co-development PartnerInnovate Phytoceuticals laboratory is integrated with full-spectrum R&D and analytical capabilities including testing, formulation, validation, genomic and metabolic fingerprinting, tissue culture and genetic development, and IP development. Melius MicroBiomics Inc. is currently incubated by Innovate Phytoceuticals in Kelowna, Canada. The partnership provides Melius with access to specialized laboratory infrastructure and expertise.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Seres Therapeutics: Clinical-stage microbiome therapeutics company developing live biotherapeutic products, including programs in ulcerative colitis (SER-287) and inflammatory diseases. Directly comparable as a developer of rationally designed microbial medicines for IBD with FDA-approved VOWST for recurrent C. difficile infection.
• Vedanta Biosciences: Developer of rationally defined consortium live biotherapeutic products for inflammatory bowel disease and other immune-mediated conditions. Directly comparable as a clinical-stage microbiome therapeutics company with an IBD focus and bacterial-consortium platform.
• Eligo Bioscience: Pioneers of engineered microbiome therapeutics using synthetic biology to program bacteria in situ. Closely comparable to Melius given its use of genetic engineering (rather than whole-strain consortia) to deliver therapeutic functions in the gut.
• Evelo Biosciences: Clinical-stage company developing orally delivered microbiome-based therapies for inflammatory diseases. Comparable as a single-strain microbial medicine developer targeting IBD and broader inflammatory indications.
• Assembly Biosciences: Biotechnology company with a microbiome-derived small-molecule and live biotherapeutic portfolio targeting serious diseases. Comparable for its early-stage pipeline orientation in engineered microbial and gut-targeted therapeutics.
• Phibro Animal Health: Animal health and nutrition company supplying swine producers with feed additives and health products addressing post-weaning stress and gut health. Directly comparable as a competitor in the pork industry for gut-health and performance-enhancing feed solutions targeted by Melius's pig GEMM.
• MaaT Pharma: European clinical-stage developer of microbiome-based therapies using standardized, high-diversity microbial consortia for inflammatory and immune-mediated diseases, including colitis and GI-inflammation indications.
• Finch Therapeutics Group: Microbiome therapeutics company developing oral Full-Spectrum Microbiota and targeted consortia products for inflammatory and infectious GI diseases. Directly comparable as a developer of live biotherapeutic products for IBD.

Broad incumbents

• AbbVie: Global biopharmaceutical leader with the dominant IBD franchise (Humira, Skyrizi, Rinvoq). Represents the entrenched standard-of-care against which any new IBD therapeutic, including Melius's MMB-003, must demonstrate clinical and commercial superiority.
• Novonesis (formerly Chr. Hansen): Global bioscience company with leading probiotic and microbial strain platforms for both human gut health and animal nutrition. Comparable as a broad incumbent in probiotic/culture ingredients and a potential CDMO or competitor for Melius's animal-health and human-GEMM products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/mmblivebio
• Facebookfacebook.com/mmblivebio
• LinkedInlinkedin.com/company/mmblivebio
• Instagraminstagram.com/mmblivebio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melius MicroBiomics